In vitro activity of gatifloxacin, a new fluoroquinolone, against 204 anaerobes compared to seven other compounds

Clin Microbiol Infect. 2003 Nov;9(11):1133-8. doi: 10.1046/j.1469-0691.2003.00773.x.

Abstract

The activity of gatifloxacin, a new fluoroquinolone derivative, was compared with the activities of ciprofloxacin, levofloxacin, amoxicillin, amoxicillin-clavulanate, imipenem, clindamycin and metronidazole against 204 anaerobes isolated from clinical specimens, by MIC determination, using the reference agar dilution method. When determining the overall activity against anaerobes, the MIC50/90 (mg/L) values were amoxicillin 16/>64, amoxicillin-clavulanate 0.125/1, imipenem 0.25/0.5, clindamycin 0.5/>256, metronidazole 1/8, ciprofloxacin 2/32, levofloxacin 1/8 and gatifloxacin 0.5/4. The broad in vitro spectrum of gatifloxacin is promising for the treatment of mixed anaerobic infections, especially those of the respiratory tract, ear, sinus, skin and soft tissues, and bite wounds. These data suggest that gatifloxacin may have a clinical role in the treatment of infections in which anaerobic pathogens are involved.

Publication types

  • Comparative Study

MeSH terms

  • Anti-Infective Agents / pharmacology*
  • Bacteria, Anaerobic / drug effects*
  • Bacteria, Anaerobic / isolation & purification
  • Fluoroquinolones / pharmacology*
  • Gatifloxacin
  • Gram-Negative Bacteria / drug effects*
  • Gram-Negative Bacteria / isolation & purification
  • Gram-Negative Bacterial Infections / microbiology
  • Gram-Positive Bacteria / drug effects*
  • Gram-Positive Bacteria / isolation & purification
  • Gram-Positive Bacterial Infections / microbiology
  • Humans
  • Microbial Sensitivity Tests

Substances

  • Anti-Infective Agents
  • Fluoroquinolones
  • Gatifloxacin